Today Zixi announced the global availability of Zixi as a Service (ZaaS), broadcast infrastructure as a service that enables media companies and service providers to quickly ingest and distribute live video over any IP with ultra-low latency.
Doses of Autologous Cell Therapy Manufactured in Under 24 Hours and Available to Patients in Approximately One Week
Clinical Trial Findings Presented at the American Society of Clinical Oncology Annual Meeting
WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV demonstrating that the investigational cell therapy is safe and well-tolerated and can stimulate immune responses in certain patients with advanced or metastatic Human Papillomavirus positive (HPV16+) tumors. The trial also showed that the company’s clinical stage manufacturing process of its autologous cell therapy is fast and reliable. The monotherapy stage trial data of the company’s first Antigen Presenting Cell (APC) platform candidate was presented at the 2021 American Society of Clinical Oncology (ASCO) annual meeting; poster presentation 2536.
BEDFORD Mass. – May 26, 2021 – Verseau Therapeutics, Inc. today announced the appointment of
John Edwards as Chief Executive Officer. John brings over 30 years of biopharmaceutical leadership
experience and has been involved in the discovery, development or global commercialization of 10 FDA approved biologics and eight biotech companies with successful exits.
WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, will present safety and tolerability, manufacturing, and antitumor activity data from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV-101 in patients with advanced or metastatic Human Papillomavirus Positive tumors at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8.
NEW YORK – Variantyx, a genetic testing company offering clinical whole-genome sequencing-based
assays, is expanding its menu to include prenatal and pan-cancer testing in the US.
The firm’s Genomic Unity Prenatal Analysis test, to be used when an ultrasound identifies structural
anomalies in a fetus, launched in January and will be available by the end of the second quarter. The
test analyzes amniotic fluid as well as blood from both parents to provide a genomic analysis of the
fetus.